<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02535884</url>
  </required_header>
  <id_info>
    <org_study_id>KKS-198</org_study_id>
    <secondary_id>DRKS00006785</secondary_id>
    <nct_id>NCT02535884</nct_id>
  </id_info>
  <brief_title>Deep Brain Stimulation (DBS) of the Globus Pallidus (GP) in Huntington's Disease (HD)</brief_title>
  <acronym>HD-DBS</acronym>
  <official_title>Deep Brain Stimulation (DBS) of the Globus Pallidus (GP) in Huntington's Disease (HD): A Prospective, Randomised, Controlled, International, Multi-centre Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heinrich-Heine University, Duesseldorf</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>KKS Netzwerk</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medtronic</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>The George Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>EHDN</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>CHDI Foundation, Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Heinrich-Heine University, Duesseldorf</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to prove the efficacy and safety of pallidal DBS in HD patients and
      to show superiority of DBS on motor function in the stimulation group compared to
      stimulation-off group
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study the efficacy and safety of pallidal Deep Brain Stimulation (DBS) in HD patients
      shall be investigated and superiority of DBS on motor function in the stimulation group
      compared to the stimulation-off group shall be shown. This study is a prospective,
      randomised, double blind, parallel group, sham-controlled, multi-centre trial. Patients in
      the stimulation group will be stimulated for three months while the stimulator in the
      sham-group will be turned off for three months. After three months the primary endpoint will
      be assessed. Afterwards the stimulator will be turned on in all patients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Anticipated">October 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>During the first 3 month the one group will be stimulated (pallidal DBS), thereafter 12 weeks open follow up, where patients in both groups are stimulated.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>UHDRS-TMS difference</measure>
    <time_frame>12 weeks postoperatively compared to baseline</time_frame>
    <description>Difference between the groups in the UHDRS total motor score (UHDRS-TMS) at 12 weeks postoperatively compared to baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>UHDRS-Chorea difference</measure>
    <time_frame>6 months postoperatively compared to baseline</time_frame>
    <description>Difference in the Unified Huntington's Disease Rating Scale (UHDRS) chorea subscore (items 14-20)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>UHDRS-bradykinesia difference</measure>
    <time_frame>6 months postoperatively compared to baseline</time_frame>
    <description>Difference in the UHDRS bradykinesia subscore (items 22-25 and 27-29)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BFMDRS difference</measure>
    <time_frame>6 months postoperatively compared to baseline</time_frame>
    <description>Difference in the Burke-Fahn-Marsden Dystonia Rating Scale (BFMDRS) motor score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reilmann Battery differences</measure>
    <time_frame>6 months postoperatively compared to baseline</time_frame>
    <description>Difference in the Q-Motor &quot;choreomotography&quot; test (Reilmann Battery)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MDRS difference</measure>
    <time_frame>6 months postoperatively compared to baseline</time_frame>
    <description>Difference in the Mattis Dementia Rating Scale (MDRS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Verbal Fluency Test difference</measure>
    <time_frame>6 months postoperatively compared to baseline</time_frame>
    <description>Difference in the Verbal Fluency Test (formal lexical, categorical, category change)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SDMT difference</measure>
    <time_frame>6 months postoperatively compared to baseline</time_frame>
    <description>Difference in the Symbol Digit Modalities Test (SDMT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>STROOP Test differences</measure>
    <time_frame>6 months postoperatively compared to baseline</time_frame>
    <description>Difference in STROOP word reading, colour naming and colour of the word naming</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HADS-SIS difference</measure>
    <time_frame>6 months postoperatively compared to baseline</time_frame>
    <description>Difference in the Hospital Anxiety and Depression Scale combined with Snaith Irritability Scale (HADS-SIS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PBA-s difference</measure>
    <time_frame>6 months postoperatively compared to baseline</time_frame>
    <description>Difference in the Problem Behaviours Assessment Short Form (PBA-s)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SF 36 difference</measure>
    <time_frame>6 months postoperatively compared to baseline</time_frame>
    <description>Difference in the Short Form (36) Health Survey (SF-36)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CGI difference</measure>
    <time_frame>6 months postoperatively compared to baseline</time_frame>
    <description>Difference in the Clinical Global Impression Scale (CGI)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Huntington Disease</condition>
  <arm_group>
    <arm_group_label>Stimulation group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in the stimulation group will be stimulated immediately after implantation of the Stimulator (ACTIVA® PC neurostimulator (Model 37601))</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-stimulation group</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Patients in the non-stimulation group will not be stimulated for the first three months after implantation of the Stimulator (ACTIVA® PC neurostimulator (Model 37601))</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ACTIVA® PC neurostimulator (Model 37601)</intervention_name>
    <description>the stimulator in the stimulation group will be turned on after implantation of the device</description>
    <arm_group_label>Stimulation group</arm_group_label>
    <arm_group_label>Non-stimulation group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinically symptomatic and genetically confirmed HD (number of CAG repeats ≥ 36)

          -  Age ≥18 years

          -  Moderate stage of the disease (UHDRS motor score ≥ 30)

          -  Chorea despite best medical treatment (UHDRS chorea subscore ≥ 10)

          -  Mattis Dementia Rating Scale ≥ 120 (or &gt; 80% of items testable independently from
             motor impairment)

          -  Patient has stable medication prior six weeks before inclusion

          -  Signed informed consent

        Exclusion Criteria:

          -  Juvenile HD (Westphal variant) or predominant bradykinesia

          -  Postural instability with UHDRS retropulsion score &gt; 2

          -  Severe comorbidity compromising operability and/or life expectancy and/or quality of
             life during the trial duration (e.g. cancer with life expectancy &lt; 6 months, NYHA 3
             and 4 rising the anaesthetic risk according to the anaesthesiologist)

          -  Acute suicidality

          -  Acute psychosis (symptoms within previous 6 months)

          -  Participation in any interventional clinical trial within 2 months before screening

          -  Cortical atrophy grade 3

          -  Patients with risk of coagulopathies and/or increased risk of haemorrhage

          -  Patients with an implanted pacemaker or defibrillator

          -  Pregnancy

          -  lactation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jan Vesper, Prof Dr.</last_name>
    <role>Study Chair</role>
    <affiliation>Dept. of Functional Neurosurgery and Stereotaxy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alfons Schnitzler, Prof Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept.of Neurology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Susanne Harnisch</last_name>
    <phone>+49 6421 2866553</phone>
    <email>susanne.harnisch@kks.uni-marburg.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Pauline Kleger</last_name>
    <phone>+49 731 50063106</phone>
    <email>Pauline.Kleger@uniklinik-ulm.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Medizinische Universität Innsbruck</name>
      <address>
        <city>Innsbruck</city>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Klaus Seppi, Prof Dr</last_name>
      <phone>+ 43 (0)512 504-25810</phone>
      <email>klaus.seppi@tirol-kliniken.at</email>
    </contact>
    <contact_backup>
      <last_name>Katherina Mair, Dr.</last_name>
      <phone>+ 43 (0)512-504-81553</phone>
      <email>katherina.mair@tirol-kliniken.at</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Charité Campus Virchow Klinikum</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Kühn, Prof Dr</last_name>
      <phone>030 450 660203</phone>
      <email>andrea.kuehn@charite.de</email>
    </contact>
    <contact_backup>
      <last_name>Josef Priller, Prof Dr</last_name>
      <phone>+49 (0)30 450-517209</phone>
      <email>josef.priller@charite.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University hospital Heinrich Heine University Düsseldorf</name>
      <address>
        <city>Düsseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan Vesper, Prof Dr</last_name>
      <phone>+49 211 81 18408</phone>
      <email>jan.vesper@med.uni-duesseldorf.de</email>
    </contact>
    <contact_backup>
      <last_name>Alfons Schnitzler, Prof Dr</last_name>
      <phone>+49 211 81 17893</phone>
      <email>Schnitza@med.uni-duesseldorf.de</email>
    </contact_backup>
    <investigator>
      <last_name>Lars Wojtecki, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Freiburg</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Volker Coenen, Prof Dr</last_name>
      <phone>+4976127050630</phone>
      <email>volker.coenen@uniklinik-freiburg.de</email>
    </contact>
    <contact_backup>
      <last_name>Eva Maria Wissner</last_name>
      <phone>+49 761 270-50670</phone>
      <email>eva-maria.wissner@uniklinik-freiburg.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University Hospital Schleswig-Holstein</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karsten Witt, Dr</last_name>
      <phone>0431 500 23810</phone>
      <email>Steffen.Paschen@uksh.de</email>
    </contact>
    <contact_backup>
      <last_name>Birte Hackelberg</last_name>
      <phone>0431-597 8519</phone>
      <email>birte.hackelberg@uksh.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Universität zu Lübeck</name>
      <address>
        <city>Lubeck Hansestadt</city>
        <zip>23562</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander Münchau, Prof Dr.</last_name>
      <phone>0451 31018215</phone>
      <email>alexander.muenchau@neuro.uni-luebeck.de</email>
    </contact>
    <contact_backup>
      <last_name>Vera Tadic</last_name>
      <phone>0451 31018214</phone>
      <email>vera.tadic@neuro.uni-luebeck.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University hospital Munich LMU</name>
      <address>
        <city>Munich</city>
        <zip>80336</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan Mehrkens, Dr</last_name>
      <phone>08970952698</phone>
      <email>jan.mehrkens@med.uni-muenchen.de</email>
    </contact>
    <contact_backup>
      <last_name>Kai Bötzel, PD Dr</last_name>
      <phone>089 7095 3673</phone>
      <email>Kai.Boetzel@med.uni-muenchen.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>kbo-Isar-Amper-Clinic Taufkirchen</name>
      <address>
        <city>Taufkirchen</city>
        <zip>84416</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ralf Marquard, Prof Dr</last_name>
      <phone>08084 934 495</phone>
      <email>Ralf.Marquard@kbo.de</email>
    </contact>
    <contact_backup>
      <last_name>Erna Jobst</last_name>
      <phone>08084 934-307</phone>
      <email>erna.jobst@kbo.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Center for Neurology</name>
      <address>
        <city>Bern</city>
        <state>Gümlingen</state>
        <zip>3073</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean Marc Burgunder, Prof Dr</last_name>
      <phone>+41 031 352 20 70</phone>
      <email>jean-marc.burgunder@dkf.unibe.ch</email>
    </contact>
    <contact_backup>
      <last_name>Michael Schüpbach</last_name>
      <phone>+41 316322168</phone>
      <email>wmms@bluewin.ch</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Inselspital, Department of Neurology</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Schüpbach, PD Dr</last_name>
      <phone>+41 31 623 32 44</phone>
      <email>wmms@bluewin.ch</email>
    </contact>
    <contact_backup>
      <last_name>Jean Marc Brugunder, Prof Dr.</last_name>
      <phone>+41 031 352 20 70</phone>
      <email>jmburgunder@bluewin.ch</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Germany</country>
    <country>Switzerland</country>
  </location_countries>
  <reference>
    <citation>Moro E, Lang AE, Strafella AP, Poon YY, Arango PM, Dagher A, Hutchison WD, Lozano AM. Bilateral globus pallidus stimulation for Huntington's disease. Ann Neurol. 2004 Aug;56(2):290-4.</citation>
    <PMID>15293283</PMID>
  </reference>
  <reference>
    <citation>Groiss SJ WL, Suedmeyer, M, Ploner M, Reck C, Voges J, SturmV, Timmermann L, Schnitzler A. Effect of bilateral pallidal deep brain stimulation in Huntington's disease: A case report. Mov Disord, Volume 21, Issue S15. Tenth International Congress of Parkinson's Disease and Movement Disorders. Kyoto 2006.</citation>
  </reference>
  <reference>
    <citation>Fasano A, Cadeddu F, Guidubaldi A, Piano C, Soleti F, Zinzi P, Bentivoglio AR. The long-term effect of tetrabenazine in the management of Huntington disease. Clin Neuropharmacol. 2008 Nov-Dec;31(6):313-8. doi: 10.1097/WNF.0b013e318166da60.</citation>
    <PMID>19050408</PMID>
  </reference>
  <reference>
    <citation>Wojtecki L, Groiss SJ, Ferrea S, Elben S, Hartmann CJ, Dunnett SB, Rosser A, Saft C, Südmeyer M, Ohmann C, Schnitzler A, Vesper J; Surgical Approaches Working Group of the European Huntington's Disease Network (EHDN). A Prospective Pilot Trial for Pallidal Deep Brain Stimulation in Huntington's Disease. Front Neurol. 2015 Aug 18;6:177. doi: 10.3389/fneur.2015.00177. eCollection 2015.</citation>
    <PMID>26347707</PMID>
  </reference>
  <reference>
    <citation>Wojtecki L, Groiss SJ, Hartmann CJ, Elben S, Omlor S, Schnitzler A, Vesper J. Deep Brain Stimulation in Huntington's Disease-Preliminary Evidence on Pathophysiology, Efficacy and Safety. Brain Sci. 2016 Aug 30;6(3). pii: E38. doi: 10.3390/brainsci6030038. Review.</citation>
    <PMID>27589813</PMID>
  </reference>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 27, 2015</study_first_submitted>
  <study_first_submitted_qc>August 28, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2015</study_first_posted>
  <last_update_submitted>September 20, 2017</last_update_submitted>
  <last_update_submitted_qc>September 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Huntington Disease</keyword>
  <keyword>DBS</keyword>
  <keyword>Chorea</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Huntington Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>After the study the data will be provided to the CHDI. The Foundation may use, and make available for use by the Foundation Collaborators, the Study Data for the following purposes: (A) to design and guide future research studies and clinical trials and (B) to support and enable the following scientific discussion and research: (1) to better understand HD or other diseases being studied, (2) that furthers the development of treatments for HD or other diseases or (3) that furthers biomedical research.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

